Abstracts taken for perfusion preparation through to its finalization was considerably longer with pamidronate: for every patient treated with pamidronate on average 3.5 could be treated with zoledronic acid. Under normal clinical practice (permanent patient vigilance and infusion times according to labeling instructions), zoledronic acid required 105 minutes less nursing time, valued at €26.25. Given that also fewer supplies were used (costing €7.29), the total cost difference reduced to an additional €32.43 with zoledronic acid. According to the clinical trials, 18.7 percentage points more patients had a complete response with zoledronic acid than with pamidronate, and average duration of complete response per treatment administered was 4.1 days longer. Thus incremental costs amounted to €173.68 per additional complete response and €7.82 per additional day of complete response. These results are dependent on clinical practice, particularly regarding the savings in personnel costs, and could be higher or lower in circumstances that are different to the most frequent scenario considered here. CONCLUSION: Compared to pamidronate, zoledronic acid considerably shortens treatment time and has an acceptable incremental cost-efficacy ratio.
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COST ANALYSIS OF CAPECITABINE VERSUS 5-FU/LV FOR COLORECTAL CANCER PATIENTS IN THE NETHERLANDS
Postma MJ 1 , van Hartskamp D 1 , Jansman FG 2 , Willemse PH 3 , Brouwers JR 1 1 Groningen University Institute for Drug Exploration/University of Groningen Research Institute of Pharmacy (GUIDE/GRIP), Groningen, Netherlands; 2 Isala Clinics, Zwolle, Netherlands; 3 University Hospital Groningen, Groningen, Netherlands OBJECTIVE: To estimate incremental costs of Capecitabine versus 5-fluorouracil/leukoverin (5FU/LV) for Dutch colon-rectal cancer patients. Treatment with capecitabine reflects a new chemotherapy for patients with colorectal cancer. Oral capecitabine has a major advantage over the current treatment with intravenous 5-FU/LV (Mayo-protocol), as it may be used at home. Furthermore, capecitabine seems to have a better safety profile than 5FU/LV. Capecitabine may be applied both in the palliative and the adjuvant setting. METHODS: We used cost analysis to estimate the pharmaco-economic profile of capecitabine. This pharmacoeconomic technique is justified as effectiveness may be assumed similar for both treatments. Costs in the analysis relate to extra drug costs of capecitabine over 5FU/LV. Benefits of capecitabine relate to reduced costs for outpatient hospital administration of 5FU/LV, for travel hence and forth and for treatment of side effects of chemotherapy. Files of 65 colorectal-cancer patients recently treated in the Isala Clinics (Zwolle, Netherlands) were investigated to assess numbers of outpatient visits for 5FU/LV administration, health-care and medications for adverse-effects and travel time. Risk reductions for adverse-effects of 5FU/LV were drawn from the literature. Costing was done using prices listed in the Dutch guideline for pharmaco-economic research. RESULTS: At the current market price, which is almost fourfold that of 5FU/LV per treatment, oral capecitabine is cost-saving compared to intravenous 5FU/LV. Costs per treatment for capecitabine were 15-25% below those for 5FU/LV, both in palliative and adjuvant settings. This result was robust in sensitivity analysis, with a 10% decrease in costs as the minimum. Cost reductions primarily relate to a decrease in hospital costs for administering 5FU/LV. CONCLUSIONS: Treatment with oral capecitabine may be cost saving for Dutch colorectal patients. Furthermore, increases in quality-of-life related to treatment in the home rather than the hospital setting may be expected.
PCN11
PROPENSITY ANALYSIS OF EPOETIN USE AND ITS IMPACT ON OVERALL COSTS OF CANCER CARE
Marchetti M 1 , Colombo G 2 , Caruggi M 2 1 IRCCS Policlinico S.Matteo, Pavia, Italy; 2 S.A.V.E. s.a.s, Milan, Italy OBJECTIVES: Epoetin reduces the transfusion rate in cancer patients undergoing chemotherapy, but it has a high cost and a variable response rate. The Anemia Guidelines Development Group recommended to limit its use when before-cycle haemoglobin is <10 g/dL and the expected drop is >1 g/dL/cycle. With the present study we aimed at assessing the propensity to use epoetin in realife practice and its economic implications. METHODS: A retrospective study enrolled 170 cancer patients in 3 Italian centres. Chart review allowed to estimate clinical outcomes and consumption of health care resources within the 3-month study period: the costs were calculated from the perspective of the National Health Care System and transformed to logarithms before analysis. An Epoetin Administration Index (EAI) was calculated through Classification and Regression Trees (CRTs). RESULTS: The population, aged 60.5 years (sd 10.2), was equally distributed among three cancer sites: gastrointestinal, head-neck-lung and ovary. Epoetin was administered to 70% of the patients, but only 5% of them had a pre-chemotherapy haemoglobin <10 g/dL. We thus calculated that epoetin was used inappropriately in 40% of the patients, while it was inappropriately not administered in 65% of the patients who got transfusions, instead. The EAI was higher in patients enrolled by center n°3, those with ovary cancer and with a higher haemoglobin or a higher anemization speed. Accuracy of the propensity score was high (accuracy 93%). The CRT splitted patients based on a haemoglobin cutoff of 9.9 g/dL: more anemic patients had a 1 : 7 odds to get epoetin, despite the guidelines. Overall cancer care costs €9,686 per epoetin-treated patient and €4,199 per trans-
